Dr. James Martin is this year’s recipient of the ATS Assembly on Respiratory Structure & Function Joseph R. Rodarte Award. Dr. Martin was nominated for this award by Dr. Basil Petrof, Director of the Meakins-Christie Laboratories.
This award is given in recognition of outstanding scientific achievement as a tribute to the outstanding attributes of the late Joseph R. Rodarte, who was an international leader in the fields of respiratory physiology and pulmonary medicine.
The award was presented at the RSF Assembly Virtual Membership Meeting held on Wednesday, June 24, 2020. Congratulations Dr. Martin!
Dr. Nicole Ezer, Dr. James Martin, Dr. Andrea Benedetti and Dr. Ben Smith, all members of the RI-MUHC’s RESP Program, have recently announced their new COVID-19 study. This study is designed to test the efficacy of ciclesonide, a steroid currently on the market, to inhibit the spread of the COVID virus in its early stages. This new trial builds on the knowledge gained from a recent study using dexamethasone on advanced cases of COVID-19.
This new study, called Contain COVID-19, which will soon be in the recruiting stage, is aimed at decreasing the severity of shortness of breath among patients who have not yet been hospitalized. Dr. Ezer states in her recent interview with Mathieu Perreault of La Presse:
« Nous espérons que ça va diminuer la gêne respiratoire et éviter l’hospitalisation en stoppant la réplication virale et en diminuant la progression de l’inflammation dans les voies respiratoires inférieures. »
Eligible participants of the study will receive the medication (or placebo) in inhaler and nasal spray form at their residence, to be used for a period of 14 days. Ciclesonide was approved by Health Canada in 2008, and side effects are fairly uncommon, mild and cease when the medication is stopped.
Dr. Ezer’s interview with Mathieu Perreault of La Presse can be read here.
Detailed information on the clinical trial as well as registration information, can be found here.